Efficacy of Lenvatinib and Sorafenib in the Real-World First-Line Treatment of Advanced-Stage Hepatocellular Carcinoma in a Taiwanese Population
Currently, atezolizumab combined with bevacizumab is the standard first-line treatment for unresectable hepatocellular carcinoma (HCC), but lenvatinib or sorafenib are still recommended for these patients for some reasons. The aim of the study was to determine the outcomes of Taiwanese patients with...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical medicine 2022-03, Vol.11 (5), p.1444 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 5 |
| container_start_page | 1444 |
| container_title | Journal of clinical medicine |
| container_volume | 11 |
| creator | Lee, Shou-Wu Yang, Sheng-Shun Lien, Han-Chung Peng, Yen-Chun Ko, Chung-Wang Lee, Teng-Yu |
| description | Currently, atezolizumab combined with bevacizumab is the standard first-line treatment for unresectable hepatocellular carcinoma (HCC), but lenvatinib or sorafenib are still recommended for these patients for some reasons. The aim of the study was to determine the outcomes of Taiwanese patients with advanced-stage HCC who received lenvatinib or sorafenib.
Data on patients with BCLC stage C HCC who were receiving lenvatinib or sorafenib as the first-line therapy from May 2018 to August 2020 was collected. The individuals with lenvatinib and sorafenib were propensity score-matched at a ratio of 1:2.
A total of 22 patients with lenvatinib and 44 patients with sorafenib were enrolled. The ORR (36.4% vs. 11.4%,
= 0.023) and DCR (81.9% vs. 56.9%,
= 0.039) were both higher in the lenvatinib group compared with the sorafenib group. The median overall survival (OS) of the lenvatinib group and the sorafenib group was 9.36 months and 8.36 months, respectively. The best median OS was detected in patients receiving lenvatinib and having an objective tumor response (11.29 months), with a significant difference (
= 0.031) compared with the other groups.
Lenvatinib, compared to sorafenib, had better ORR and DCR, but similar OS, in Taiwanese patients with advanced-stage HCC. The patients with an objective tumor response had a better OS. |
| doi_str_mv | 10.3390/jcm11051444 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8911194</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2638718277</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-fbd184f4f9b6ee41339371d253ad77990d3fc7c27fbb5dfa5edb967050da27503</originalsourceid><addsrcrecordid>eNpdkVFrFDEUhYMotqx98l0CvghlNJkkm5kXoSytFRYUu-LjcCe5abPMJGsyu9J_4U82Q2tZzctNuB-Hc3IIec3ZeyFa9mFrRs6Z4lLKZ-S0ZlpXTDTi-dH9hJzlvGXlNI2suX5JToSql40S6pT8vnTOGzD3NDq6xnCAyQffUwiW3sQEDueXD3S6Q_oNYah-xDRYeuVTnqq1D0g3CWEaMUyzxIU9QDBoq5sJbpFe4w6maHAY9gMkuoJkfIgjzIpAN-B_QcCM9GvcFWDyMbwiLxwMGc8e54J8v7rcrK6r9ZdPn1cX68pIrabK9ZY30knX9ktEyctnCM1trQRYrduWWeGMNrV2fa-sA4W2b5eaKWah1oqJBfn4oLvb9yNaU_wnGLpd8iOk-y6C7_7dBH_X3cZD17Sc81YWgXePAin-3GOeutHnOWlJFPe5q5ei0byptS7o2__QbdynUOLNlNZSNCXBgpw_UCbFnBO6JzOcdXPZ3VHZhX5z7P-J_Vut-ANr7qbv</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2637743841</pqid></control><display><type>article</type><title>Efficacy of Lenvatinib and Sorafenib in the Real-World First-Line Treatment of Advanced-Stage Hepatocellular Carcinoma in a Taiwanese Population</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Lee, Shou-Wu ; Yang, Sheng-Shun ; Lien, Han-Chung ; Peng, Yen-Chun ; Ko, Chung-Wang ; Lee, Teng-Yu</creator><creatorcontrib>Lee, Shou-Wu ; Yang, Sheng-Shun ; Lien, Han-Chung ; Peng, Yen-Chun ; Ko, Chung-Wang ; Lee, Teng-Yu</creatorcontrib><description>Currently, atezolizumab combined with bevacizumab is the standard first-line treatment for unresectable hepatocellular carcinoma (HCC), but lenvatinib or sorafenib are still recommended for these patients for some reasons. The aim of the study was to determine the outcomes of Taiwanese patients with advanced-stage HCC who received lenvatinib or sorafenib.
Data on patients with BCLC stage C HCC who were receiving lenvatinib or sorafenib as the first-line therapy from May 2018 to August 2020 was collected. The individuals with lenvatinib and sorafenib were propensity score-matched at a ratio of 1:2.
A total of 22 patients with lenvatinib and 44 patients with sorafenib were enrolled. The ORR (36.4% vs. 11.4%,
= 0.023) and DCR (81.9% vs. 56.9%,
= 0.039) were both higher in the lenvatinib group compared with the sorafenib group. The median overall survival (OS) of the lenvatinib group and the sorafenib group was 9.36 months and 8.36 months, respectively. The best median OS was detected in patients receiving lenvatinib and having an objective tumor response (11.29 months), with a significant difference (
= 0.031) compared with the other groups.
Lenvatinib, compared to sorafenib, had better ORR and DCR, but similar OS, in Taiwanese patients with advanced-stage HCC. The patients with an objective tumor response had a better OS.</description><identifier>ISSN: 2077-0383</identifier><identifier>EISSN: 2077-0383</identifier><identifier>DOI: 10.3390/jcm11051444</identifier><identifier>PMID: 35268535</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Clinical medicine ; Growth factors ; Hepatitis B ; Hepatitis C ; Hypertension ; Inhibitor drugs ; Laboratories ; Liver cancer ; Liver diseases ; Medical prognosis ; Patients ; Survival analysis ; Targeted cancer therapy</subject><ispartof>Journal of clinical medicine, 2022-03, Vol.11 (5), p.1444</ispartof><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 by the authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-fbd184f4f9b6ee41339371d253ad77990d3fc7c27fbb5dfa5edb967050da27503</citedby><cites>FETCH-LOGICAL-c475t-fbd184f4f9b6ee41339371d253ad77990d3fc7c27fbb5dfa5edb967050da27503</cites><orcidid>0000-0002-2412-2665</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8911194/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8911194/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35268535$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lee, Shou-Wu</creatorcontrib><creatorcontrib>Yang, Sheng-Shun</creatorcontrib><creatorcontrib>Lien, Han-Chung</creatorcontrib><creatorcontrib>Peng, Yen-Chun</creatorcontrib><creatorcontrib>Ko, Chung-Wang</creatorcontrib><creatorcontrib>Lee, Teng-Yu</creatorcontrib><title>Efficacy of Lenvatinib and Sorafenib in the Real-World First-Line Treatment of Advanced-Stage Hepatocellular Carcinoma in a Taiwanese Population</title><title>Journal of clinical medicine</title><addtitle>J Clin Med</addtitle><description>Currently, atezolizumab combined with bevacizumab is the standard first-line treatment for unresectable hepatocellular carcinoma (HCC), but lenvatinib or sorafenib are still recommended for these patients for some reasons. The aim of the study was to determine the outcomes of Taiwanese patients with advanced-stage HCC who received lenvatinib or sorafenib.
Data on patients with BCLC stage C HCC who were receiving lenvatinib or sorafenib as the first-line therapy from May 2018 to August 2020 was collected. The individuals with lenvatinib and sorafenib were propensity score-matched at a ratio of 1:2.
A total of 22 patients with lenvatinib and 44 patients with sorafenib were enrolled. The ORR (36.4% vs. 11.4%,
= 0.023) and DCR (81.9% vs. 56.9%,
= 0.039) were both higher in the lenvatinib group compared with the sorafenib group. The median overall survival (OS) of the lenvatinib group and the sorafenib group was 9.36 months and 8.36 months, respectively. The best median OS was detected in patients receiving lenvatinib and having an objective tumor response (11.29 months), with a significant difference (
= 0.031) compared with the other groups.
Lenvatinib, compared to sorafenib, had better ORR and DCR, but similar OS, in Taiwanese patients with advanced-stage HCC. The patients with an objective tumor response had a better OS.</description><subject>Clinical medicine</subject><subject>Growth factors</subject><subject>Hepatitis B</subject><subject>Hepatitis C</subject><subject>Hypertension</subject><subject>Inhibitor drugs</subject><subject>Laboratories</subject><subject>Liver cancer</subject><subject>Liver diseases</subject><subject>Medical prognosis</subject><subject>Patients</subject><subject>Survival analysis</subject><subject>Targeted cancer therapy</subject><issn>2077-0383</issn><issn>2077-0383</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNpdkVFrFDEUhYMotqx98l0CvghlNJkkm5kXoSytFRYUu-LjcCe5abPMJGsyu9J_4U82Q2tZzctNuB-Hc3IIec3ZeyFa9mFrRs6Z4lLKZ-S0ZlpXTDTi-dH9hJzlvGXlNI2suX5JToSql40S6pT8vnTOGzD3NDq6xnCAyQffUwiW3sQEDueXD3S6Q_oNYah-xDRYeuVTnqq1D0g3CWEaMUyzxIU9QDBoq5sJbpFe4w6maHAY9gMkuoJkfIgjzIpAN-B_QcCM9GvcFWDyMbwiLxwMGc8e54J8v7rcrK6r9ZdPn1cX68pIrabK9ZY30knX9ktEyctnCM1trQRYrduWWeGMNrV2fa-sA4W2b5eaKWah1oqJBfn4oLvb9yNaU_wnGLpd8iOk-y6C7_7dBH_X3cZD17Sc81YWgXePAin-3GOeutHnOWlJFPe5q5ei0byptS7o2__QbdynUOLNlNZSNCXBgpw_UCbFnBO6JzOcdXPZ3VHZhX5z7P-J_Vut-ANr7qbv</recordid><startdate>20220306</startdate><enddate>20220306</enddate><creator>Lee, Shou-Wu</creator><creator>Yang, Sheng-Shun</creator><creator>Lien, Han-Chung</creator><creator>Peng, Yen-Chun</creator><creator>Ko, Chung-Wang</creator><creator>Lee, Teng-Yu</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2412-2665</orcidid></search><sort><creationdate>20220306</creationdate><title>Efficacy of Lenvatinib and Sorafenib in the Real-World First-Line Treatment of Advanced-Stage Hepatocellular Carcinoma in a Taiwanese Population</title><author>Lee, Shou-Wu ; Yang, Sheng-Shun ; Lien, Han-Chung ; Peng, Yen-Chun ; Ko, Chung-Wang ; Lee, Teng-Yu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-fbd184f4f9b6ee41339371d253ad77990d3fc7c27fbb5dfa5edb967050da27503</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Clinical medicine</topic><topic>Growth factors</topic><topic>Hepatitis B</topic><topic>Hepatitis C</topic><topic>Hypertension</topic><topic>Inhibitor drugs</topic><topic>Laboratories</topic><topic>Liver cancer</topic><topic>Liver diseases</topic><topic>Medical prognosis</topic><topic>Patients</topic><topic>Survival analysis</topic><topic>Targeted cancer therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, Shou-Wu</creatorcontrib><creatorcontrib>Yang, Sheng-Shun</creatorcontrib><creatorcontrib>Lien, Han-Chung</creatorcontrib><creatorcontrib>Peng, Yen-Chun</creatorcontrib><creatorcontrib>Ko, Chung-Wang</creatorcontrib><creatorcontrib>Lee, Teng-Yu</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, Shou-Wu</au><au>Yang, Sheng-Shun</au><au>Lien, Han-Chung</au><au>Peng, Yen-Chun</au><au>Ko, Chung-Wang</au><au>Lee, Teng-Yu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of Lenvatinib and Sorafenib in the Real-World First-Line Treatment of Advanced-Stage Hepatocellular Carcinoma in a Taiwanese Population</atitle><jtitle>Journal of clinical medicine</jtitle><addtitle>J Clin Med</addtitle><date>2022-03-06</date><risdate>2022</risdate><volume>11</volume><issue>5</issue><spage>1444</spage><pages>1444-</pages><issn>2077-0383</issn><eissn>2077-0383</eissn><abstract>Currently, atezolizumab combined with bevacizumab is the standard first-line treatment for unresectable hepatocellular carcinoma (HCC), but lenvatinib or sorafenib are still recommended for these patients for some reasons. The aim of the study was to determine the outcomes of Taiwanese patients with advanced-stage HCC who received lenvatinib or sorafenib.
Data on patients with BCLC stage C HCC who were receiving lenvatinib or sorafenib as the first-line therapy from May 2018 to August 2020 was collected. The individuals with lenvatinib and sorafenib were propensity score-matched at a ratio of 1:2.
A total of 22 patients with lenvatinib and 44 patients with sorafenib were enrolled. The ORR (36.4% vs. 11.4%,
= 0.023) and DCR (81.9% vs. 56.9%,
= 0.039) were both higher in the lenvatinib group compared with the sorafenib group. The median overall survival (OS) of the lenvatinib group and the sorafenib group was 9.36 months and 8.36 months, respectively. The best median OS was detected in patients receiving lenvatinib and having an objective tumor response (11.29 months), with a significant difference (
= 0.031) compared with the other groups.
Lenvatinib, compared to sorafenib, had better ORR and DCR, but similar OS, in Taiwanese patients with advanced-stage HCC. The patients with an objective tumor response had a better OS.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>35268535</pmid><doi>10.3390/jcm11051444</doi><orcidid>https://orcid.org/0000-0002-2412-2665</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2077-0383 |
| ispartof | Journal of clinical medicine, 2022-03, Vol.11 (5), p.1444 |
| issn | 2077-0383 2077-0383 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8911194 |
| source | MDPI - Multidisciplinary Digital Publishing Institute; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access |
| subjects | Clinical medicine Growth factors Hepatitis B Hepatitis C Hypertension Inhibitor drugs Laboratories Liver cancer Liver diseases Medical prognosis Patients Survival analysis Targeted cancer therapy |
| title | Efficacy of Lenvatinib and Sorafenib in the Real-World First-Line Treatment of Advanced-Stage Hepatocellular Carcinoma in a Taiwanese Population |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T05%3A25%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20Lenvatinib%20and%20Sorafenib%20in%20the%20Real-World%20First-Line%20Treatment%20of%20Advanced-Stage%20Hepatocellular%20Carcinoma%20in%20a%20Taiwanese%20Population&rft.jtitle=Journal%20of%20clinical%20medicine&rft.au=Lee,%20Shou-Wu&rft.date=2022-03-06&rft.volume=11&rft.issue=5&rft.spage=1444&rft.pages=1444-&rft.issn=2077-0383&rft.eissn=2077-0383&rft_id=info:doi/10.3390/jcm11051444&rft_dat=%3Cproquest_pubme%3E2638718277%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2637743841&rft_id=info:pmid/35268535&rfr_iscdi=true |